A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma

By Rose P.G.   Gordon N.H.   Fusco N.   Fluellen L.   Rodriguez M.   Ingalls S.T.   Hoppel C.L.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 228-234

Elsevier

Access to resources Recommend Favorite

Oral Treosulfan as Second-Line Treatment in Platinum-Resistant Ovarian Cancer: A Phase II Study

By Keldsen N.   Madsen E.L.   Havsteen H.   Kamby C.   Laursen L.   Sandberg E.   on behalf of The Danish Ovarian Cancer Study Group  

Gynecologic Oncology, Vol. 69, Iss. 2, 1998-05 ,pp. : 100-102

Elsevier

Access to resources Recommend Favorite

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

By Manetta A.   Blessing J.A.   Hurteau J.A.  

Gynecologic Oncology, Vol. 68, Iss. 1, 1998-01 ,pp. : 45-46

Elsevier

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Verschraegen C.F.   Westphalen S.   Hu W.   Loyer E.   Kudelka A.   Volker P.   Kavanagh J.   Steger M.   Schulz K.-D.   Emons G.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 552-559

Elsevier

Access to resources Recommend Favorite